Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You and Your Team.

Learn More →

Statin Therapy for Healthy Men Identified as “Increased Risk”

Statin Therapy for Healthy Men Identified as “Increased Risk” VIEWPOINT Scan for Author Audio Interview Statin Therapy for Healthy Men Identified as “Increased Risk” Evidence Supporting Primary Prevention Michael J. Blaha, MD, MPH The WOSCOPS enrolled 6595 men aged 45 to 64 years with Khurram Nasir, MD, MPH no previous history of myocardial infarction and a mean (SD) Roger S. Blumenthal, MD plasma cholesterol level of 272 (23) mg/dL. Treatment with pravastatin, 40 mg, resulted in a 31% reduction in myocar- Should a 55-year-old man who is otherwise well, with sys- dial infarction and CHD-related death (248 vs 174 events and tolic blood pressure of 110 mm Hg, total cholesterol of 135 vs 106 deaths for placebo vs pravastatin, respectively). 250 mg/dL, and no family history of premature CHD be Similarly, the AFCAPS/TexCAPS randomized 6605 asymp- treated with a statin? —Yes. tomatic adults with a mean (SD) LDL-C level of 150 (17) mg/dL and low HDL-C (36 [5] mg/dL in men and 40 [5] THEROSCLEROTIC CORONARY HEART DISEASE mg/dL in women) to lovastatin, 20 to 40 mg, vs placebo. (CHD) is the most common cause of morbidity Treatment with lovastatin reduced the incidence of first ma- and mortality in the world. The “lipid hypoth- jor coronary events by http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png JAMA American Medical Association

Statin Therapy for Healthy Men Identified as “Increased Risk”

JAMA , Volume 307 (14) – Apr 11, 2012

Loading next page...
 
/lp/american-medical-association/statin-therapy-for-healthy-men-identified-as-increased-risk-zwkNhwRq8U
Publisher
American Medical Association
Copyright
Copyright 2012 American Medical Association. All Rights Reserved. Applicable FARS/DFARS Restrictions Apply to Government Use.
ISSN
0098-7484
eISSN
1538-3598
DOI
10.1001/jama.2012.425
pmid
22496260
Publisher site
See Article on Publisher Site

Abstract

VIEWPOINT Scan for Author Audio Interview Statin Therapy for Healthy Men Identified as “Increased Risk” Evidence Supporting Primary Prevention Michael J. Blaha, MD, MPH The WOSCOPS enrolled 6595 men aged 45 to 64 years with Khurram Nasir, MD, MPH no previous history of myocardial infarction and a mean (SD) Roger S. Blumenthal, MD plasma cholesterol level of 272 (23) mg/dL. Treatment with pravastatin, 40 mg, resulted in a 31% reduction in myocar- Should a 55-year-old man who is otherwise well, with sys- dial infarction and CHD-related death (248 vs 174 events and tolic blood pressure of 110 mm Hg, total cholesterol of 135 vs 106 deaths for placebo vs pravastatin, respectively). 250 mg/dL, and no family history of premature CHD be Similarly, the AFCAPS/TexCAPS randomized 6605 asymp- treated with a statin? —Yes. tomatic adults with a mean (SD) LDL-C level of 150 (17) mg/dL and low HDL-C (36 [5] mg/dL in men and 40 [5] THEROSCLEROTIC CORONARY HEART DISEASE mg/dL in women) to lovastatin, 20 to 40 mg, vs placebo. (CHD) is the most common cause of morbidity Treatment with lovastatin reduced the incidence of first ma- and mortality in the world. The “lipid hypoth- jor coronary events by

Journal

JAMAAmerican Medical Association

Published: Apr 11, 2012

References